Filter Results
:
(16)
Show Results For
- All HBS Web (29)
- Faculty Publications (4)
Show Results For
- All HBS Web (29)
- Faculty Publications (4)
Page 1 of
16
Results
Sort by
- 2019
- Chapter
Characterizing the Drug Development Pipeline for Precision Medicines
By: Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
BOOK ABSTRACT: Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement...
View Details
Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern. "Characterizing the Drug Development Pipeline for Precision Medicines." Chap. 5 in Economic Dimensions of Personalized and Precision Medicine, edited by Ernest R. Berndt, Dana P. Goldman, and John W. Rowe, 115–158. University of Chicago Press, 2019.
- 06 Sep 2022
- Research & Ideas
Curbing an Unlikely Culprit of Rising Drug Prices: Pharmaceutical Donations
Prescription drug costs continue to climb in the United States, but tightening a loophole in a federal law may help curb rising expenses, according to research published this week in Health Affairs. Efforts to control US health care...
View Details
- October 2013
- Case
FasterCures: Removing Barriers to Treatments
By: Richard G. Hamermesh and James Weber
In mid-2013, as FasterCures celebrated its 10th anniversary as a center of the Milken Institute, Executive Director Margaret Anderson thought about what the organization should do to ensure it had even more impact in its next 10 years. FasterCures was a non-profit... View Details
Keywords:
Health Care;
Health Care Industry;
Health Care Policy;
Health Services;
Healthcare;
Healthcare Reform;
Healthcare Ventures;
Nonprofit;
Non-profit Management;
Not-for-profit;
Incubator;
Accelerator;
Venture Philanthropy;
Medical Services;
Medical Solutions;
Medical Research;
Medical Treatment;
Clinical Trials;
Drug Reimbursement;
Early Stage;
Early Stage Research Funding;
Early Stage Funding;
Milken Institute;
Michael Milken;
David Baltimore;
Partnering For Cures;
National Institutes Of Health;
Cancer Care In The U.S.;
Cancer Care Services;
Policy-making;
Health Care and Treatment;
Health;
Health Testing and Trials;
Entrepreneurship;
Social Entrepreneurship;
Nonprofit Organizations;
Policy;
Health Industry;
United States;
District of Columbia
Hamermesh, Richard G., and James Weber. "FasterCures: Removing Barriers to Treatments." Harvard Business School Case 814-003, October 2013.
- March 2014
- Editorial
Limits on Use of Health Economic Assessments for Rare Diseases
By: Hanna I. Hyry, Ariel Dora Stern, Jonathan CP Roos and Timothy M. Cox
Funding of expensive treatments for rare ('orphan') diseases is contentious. These agents fare poorly on 'efficiency' or health economic measures, such as the QALY, because of high cost and frequently poor gains in quality of life and survival. We show that...
View Details
Hyry, Hanna I., Ariel Dora Stern, Jonathan CP Roos, and Timothy M. Cox. "Limits on Use of Health Economic Assessments for Rare Diseases." hcu016. QJM: An International Journal of Medicine 107, no. 3 (March 2014): 241–245.
- 2023
- Article
Dynamic HTA for Digital Health Solutions: Opportunities and Challenges for Patient-Centered Evaluation
By: Jan B. Brönneke, Annika Herr, Simon Reif and Ariel D. Stern
Germany’s 2019 Digital Healthcare Act (Digitale-Versorgung-Gesetz, or DVG) created a number of opportunities for the digital transformation of the health care delivery system. Key among these was the creation of a reimbursement pathway for patient-centered digital...
View Details
Keywords:
Digital Transformation;
Applications and Software;
Product Development;
Insurance;
Policy;
Health Industry;
Germany
Brönneke, Jan B., Annika Herr, Simon Reif, and Ariel D. Stern. "Dynamic HTA for Digital Health Solutions: Opportunities and Challenges for Patient-Centered Evaluation." International Journal of Technology Assessment in Health Care 39, no. 1 (2023).
- 09 Aug 2016
- First Look
August 9, 2016
https://pubwww.hbs.edu/faculty/Pages/item.aspx?num=51304 The Impact of the Entry of Biosimilars: Evidence from Europe By: Scott Morton, Fiona, Ariel Dora Stern, and Scott Stern Abstract—Biologic drugs (therapeutic proteins or...
View Details
Keywords:
Sean Silverthorne
- 10 Oct 2007
- First Look
First Look: First Look: October 10
broad-based therapies. Instead, the focus should be on enrolling subpopulations, based on diagnostic testing, in trials of targeted drug treatments and on monitoring and assessing effectiveness after drugs...
View Details
Keywords:
Martha Lagace
- 16 Dec 2014
- First Look
First Look: December 16
Michael E., and Robert S. Kaplan Abstract—Improving provider incentives and reimbursement must become a central component in health care reform. Reimbursement through bundled payments-a single payment that...
View Details
Keywords:
Sean Silverthorne
- 15 Jul 2013
- Research & Ideas
Five Imperatives for Improving Health Care
to be reimbursed very well by insurance companies, and they've set themselves up to do a lot of those particular procedures? "Those are two different scenarios, and we'd like to see more of the former than the latter." Promoting...
View Details
- 08 Apr 2009
- Research & Ideas
Clayton Christensen on Disrupting Health Care
describe it—in a way that applies to health care or any industry—is innovation that transforms a product or service that historically has been very complicated and expensive into something that is affordable and simple to use. Q: In your book, you identify...
View Details
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
worldwide pharmaceuticals spending, according to Food and Drug Administration Commissioner Mark McClellan.) One problem, several panelists noted, is that European healthcare systems do not reimburse the high...
View Details
- 16 Jul 2008
- Op-Ed
What Should Employers Do about Health Care?
frequently in search of a better deal, which has meant that their employees needed to switch as well. They have tried to pare back covered services, thrown up barriers to expensive drugs and treatments, and recently, begun to pass more...
View Details
- 03 Jul 2012
- Research & Ideas
HBS Faculty on Supreme Court Health Care Ruling
of diabetes; cardiovascular disease; cancer, spine and joint disease; and metabolic syndrome. One of the most important aspects of AHCA is the creation of designated accountable care organizations (ACOs). ACOs shift reimbursement away...
View Details
- 22 May 2020
- In Practice
Post-COVID Health Care: More Screens, Less Red Tape?
techniques, the changes in reimbursement for free-standing ambulatory surgery centers, the rise of telemedicine, and consumers’ preferences for surgery outside of the hospitals, will be accelerated by the closing of hospitals for...
View Details
Keywords:
by Danielle Kost
- 12 Feb 2019
- First Look
New Research and Ideas, February 12, 2019
Devices: Challenges and Opportunities for U.S. Regulators and Innovators By: Gordon, William J., and Ariel Dora Stern Abstract— Software has become an increasingly important component of medical device technology. Through legislation like the 21st Century Cures Act as...
View Details
Keywords:
Dina Gerdeman
- 04 Feb 2014
- First Look
First Look: February 4
system. It's complicated, takes a long time, and is very expensive. Should FasterCures reorganize to better understand this issue and make a high-level push to improve it? Or perhaps the company should look at drug View Details
Keywords:
Sean Silverthlorne